Hypoadiponectinemia in obese and diabetic subjects in the State of Qatar

International Journal of Diabetes and Metabolism

Volumn 16, Issue 3, 2008, Pages 123-129

  Rizk, N ^a   Awni, R ^b   Osman, M ^b   Zirie, M ^b  

^a QATAR UNIVERSITY   (Qatar)

^b HMC   (Qatar)

Author keywords

Adiponectin; CVD; Diabetes; Metabolic syndrome; Obesity; Qatar

Indexed keywords

ADIPONECTIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PROTEIN BLOOD LEVEL; QATAR; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

EID: 70350323645     PISSN: 16067754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106:473-481.
2. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003; 108:1541-1545.
3. Kondo H, Shimomura I, Matsukawa Y, et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002; 51:2325-2328.
4. Yamauchi T, Hara K, Kubota N, et al. Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3:243-254.
5. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8:1288-1295.
6. Vasseur F, Helbecque N, Dina C, et al. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet 2002; 11:2607-2614.
7. Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin levels are not associated with fat oxidation in humans. Obes Res 2002; 10:1016-1020.
8. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
9. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20:1595-1599.
10. Giannessi D, Maltinti M, Del Ry S. Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk. Pharmacol Res 2007; 56:459-467.
11. WHO Global InfoBase. Retrieved July 25, 2008. Available on: [u http:// www.who.int/infobase u]/report.aspx?rid=111&iso=QAT
12. International Diabetes Federation. Retrieved July 25, 2008. Available on: [u http://www.eatlas.idf.org u]/Prevalence.
13. WHO Expert Committee physical status. 1995. The use and interpretation of Anthropometry. WHO Technical Report Series, Geneva, no.854, WHO.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
15. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
16. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
17. Yang WS, Lee WJ, Funahashi T, et al. Plasma adiponectin levels in overweight and obese Asians. Obes Res 2002; 10:1104-1110.
18. Snehalatha C, Mukesh B, Simon M, et al. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care 2003; 26: 3226-3229.
19. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86:1930-1935.
20. Goldstein BJ: Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 2002; 90:3G-10G.
21. Mohlig M, Wegewitz U, Osterhoff M, et al: Insulin decreases human adiponectin plasma levels. Horm Metab Res 2002; 34:655-658.
22. Fasshauer M, Klein J, Neumann S, et al. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002; 290:1084-1089.
23. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51:2968-2974.
24. Furuta M, Tamai M, Hanabusa T, et al. Serum adiponectin is associated with fasting serum C-peptide in non-obese diabetic patients. Diabetes Res Clin Pract 2006; 72:302-307.
25. Lin KD, Chang YH, Wang CL, et al. Thiazolidinedione addition reduces the serum retinol-binding protein 4 in type 2 diabetic patients treated with metformin and sulfonylurea. Transl Res 2008; 151:309-314.
26. Abbasi F, Chu JW, Lamendola C, et al. Discrimination between obesity and insulin resistance in the relationship with adiponectin. Diabetes 2004; 53:585-590.
27. Kim MJ, Yoo KH, Park HS, et al. Plasma adiponectin and insulin resistance in Korean type 2 diabetes mellitus. Yonsei Med J 2005; 46:42-50.
28. Buemann B, Astrup A, Pedersen O, et al. Possible role of adiponectin and insulin sensitivity in mediating the favorable effects of lower body fat mass on blood lipids. J Clin Endocrinol Metab 2006; 91:1698-1704.
29. Nishida M, Funahashi T, Shimomura I. Pathophysiological significance of adiponectin. Med Mol Morphol 2007; 40:55-67.
30. Rabin KR, Kamari Y, Avni I, et al. Adiponectin: linking the metabolic syndrome to its cardiovascular consequences. Expert Rev Cardiovasc Ther 2005; 3: 465-471.
31. Salas-Salvado J, Granada M, Bullo M, Corominas A, Casas P, Foz M. Plasma adiponectin distribution in a Mediterranean population and its association with cardiovascular risk factors and metabolic syndrome. Metabolism 2007; 56:1486-1492. 32 Eckel RH. Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic CVD. Proc Nutr Soc 2007; 66:82-95.
32. Kuller LH, Grandits G, Cohen JD, et al. Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. Atherosclerosis 2007; 195:122-128.
33. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23:85-89.
34. Ouchi N, Kihara S, Funahashi T, et al. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003; 14:561-566.
35. Hanley AJ, Bowden D, Wagenknecht LE, et al. Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J Clin Endocrinol Metab 2007; 92:2665-2671.
36. Nishizawa H, Shimomura I, Kishida K, et al: Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002; 51:2734-2741.
37. Gui Y, Silha JV, Murphy LJ. Sexual dimorphism and regulation of resistin, adiponectin, and leptin expression in the mouse. Obes Res 2004; 12:1481-1491.